A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Johnson & Johnson submitted to the FDA trial data that it hopes will lead to the first approved treatment for smoldering myeloma. Also in the news: 3D mammograms gain popularity; companies want to ...

Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...

Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23 months median Overall Survival from date of ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...

GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.

The results will be welcomed by boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and ...